by Matthew Johnson | May 27, 2022 | Final Written Decisions, PTAB News
By Jareli Reynoso Gutierrez and Matt Johnson – On March 3, 2022, Andrew Hirshfeld, the Commissioner for Patents and acting Director of the USPTO, issued the third post-Arthrex grant of Director Review for two separate Final Written Decisions issued by the PTAB...
by Matthew Johnson | May 18, 2022 | Final Written Decisions, Time Limits
By Haytham Soliman and Matt Johnson – In Laboratoire Francais du Fractionnement et des Biotechnologies S.A. v. Novo Nordisk Healthcare AG, the Patent Trial and Appeal Board (PTAB) denied the Petitioner’s motion to terminate the inter partes review (IPR) and to...
by Matthew Johnson | May 13, 2022 | PTAB News, PTAB Trial Basics
By Haytham Soliman and Matt Johnson – The PTAB recently denied institution of inter partes review (IPR) for claims 1 and 46 of U.S. 7,464,040 in eClinicalWorks, LLC et al. v. Decapolis Systems, LLC, IPR2022-0229, Paper 10 (PTAB April 13, 2022). The denial was...
by Matthew Johnson | May 2, 2022 | 325(d) issues, Prior Art Issues, PTAB News
By Haytham Soliman and Matt Johnson – The Board denied post grant review in Palo Alto Networks, Inc. v. Centripetal Networks, Inc. under 35 U.S.C. § 325(d) after applying the Advanced Bionics[1] framework as informed by the factors outlined in Becton.[2] ...
by Matthew Johnson | Apr 6, 2022 | PTAB News
On April 5, 2022, the Senate confirmed Kathi Vidal as the new Director of the USPTO by voice vote. President Joe Biden nominated Vidal for the post last October. The position had been vacant since Andrei Iancu resigned in January 2021. The duties of the Director...
